Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

Trial Profile

Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic, First in Man Study, of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2016

At a glance

  • Drugs SAR 125844 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms SARMET
  • Sponsors Sanofi
  • Most Recent Events

    • 02 Feb 2016 Planned End Date changed from 1 May 2017 to 1 Apr 2017, as reported by the ClinicalTrials.gov record.
    • 02 Feb 2016 Planned primary completion date changed from 1 May 2017 to 1 Apr 2017, as reported by the ClinicalTrials.gov record.
    • 30 Jul 2015 Status changed from active, no longer recruiting to completed, as reported in the media release by Ligand Pharmaceuticals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top